ConductScience.org, home

Gene · 4919

ROR1: ROR family WNT receptor 1

12 sourcesgene-search-2026-11-11-0.2.0

Download JSON
Cite this record

ConductScience Library. ROR1: ROR family WNT receptor 1. Genes, record 4919. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/4919

On this page

Gene

Symbol
ROR1
HGNC
Name
ROR family WNT receptor 1
HGNC
NCBI Gene ID
4919
NCBI Gene
HGNC ID
HGNC:10256
HGNC
Ensembl
ENSG00000185483
NCBI Gene
Aliases
NTRKR1, dJ537F10.1
NCBI Gene
Type
protein-coding
NCBI Gene

Proteins1

Reviewed human proteins whose Swiss-Prot entry states the gene.

UniProt entryProteinLengthStructuresGene stated in
Q01973Inactive tyrosine-protein kinase transmembrane receptor ROR19375Ensembl, GeneID, HGNC

Source UniProt

Patents160

Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.

PublicationPublishedSEQ ID NOProteinSource
EP 4777551 A12026-07-229Q01973Espacenet
EP 4772535 A12026-07-0895Q01973Espacenet
JP 2026515434 A2026-05-1872Q01973Espacenet
EP 4696329 A12026-02-1887Q01973Espacenet
JP 2026004568 A2026-01-1461152Q01973Espacenet
JP 2025538110 A2025-11-2647Q01973Espacenet
KR 1020250163373 A2025-11-2087Q01973Espacenet
EP 4650780 A22025-11-198890Q01973Espacenet
EP 4641201 A22025-10-299118Q01973Espacenet
JP 2025147176 A2025-10-0611535Q01973Espacenet

1 to 10 of 160

See all 160 patents

Drugs1

Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.

DrugChEMBL IDMechanismAction
CIRMTUZUMABCHEMBL4297728Inactive tyrosine-protein kinase transmembrane receptor ROR1 inhibitorINHIBITOR

Source ChEMBL

Trials17

Trials of those drugs. A trial joins the gene only through a drug that acts on it.

TrialDrugPhaseResults first postedSource
NCT06890884CIRMTUZUMABPHASE2ClinicalTrials.gov
NCT06717347CIRMTUZUMABPHASE3ClinicalTrials.gov
NCT06395103CIRMTUZUMABPHASE1/PHASE2ClinicalTrials.gov
NCT05562830CIRMTUZUMABPHASE1/PHASE2ClinicalTrials.gov
NCT05458297CIRMTUZUMABPHASE2ClinicalTrials.gov
NCT05431179CIRMTUZUMABPHASE3ClinicalTrials.gov
NCT05406401CIRMTUZUMABPHASE2ClinicalTrials.gov
NCT05156905CIRMTUZUMABPHASE1ClinicalTrials.gov
NCT05144841CIRMTUZUMABPHASE2ClinicalTrials.gov
NCT05139017CIRMTUZUMABPHASE2/PHASE3ClinicalTrials.gov

1 to 10 of 17

See all 17 trials

NIH grants1,179

NIH grants whose papers are about the gene, through NIH's grant-paper links.

GrantTitleROR1 papersNewest fiscal year
P30CA008748Cancer Center Support Grant312025
P30CA016672Cancer Center Support Grant262025
R01CA114536Novel synthetic receptors with improved antigen specificity and specificity for cancer therapy212025
P30CA016058Cancer Center Support Grant102025
P30CA069533OHSU Knight Cancer Institute72025
P01CA018029Adult Leukemia Research Center62025
P30CA010815Consolidated Basic Cancer Research Program62025
P30CA015704Cancer Center Support Grant62025
P30CA076292Moffitt Cancer Center Support Grant62025
R01CA204484Novel Enediyne-Based Antibody-Drug Conjugates for Cancers62025

1 to 10 of 1,179Source NIH's project files

See all 1,179 nih grants

Papers2,258

Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.

TitleJournalYearPMIDFound bySource
Inhibition of ROR1 signaling with zilovertamab plus ibrutinib in chronic lymphocytic leukemia: safety, mechanistic insights, and an exploratory signal in del(17p) disease.Leukemia202642827116PubTator, text miningPubMed
SLV-404, an anti-RYK antibody-drug conjugate, is effective in Richter transformation patient-derived xenografts.Hemasphere202642824998PubTator, text miningPubMed
ROR1 upregulation after CD19-CAR T-cell relapse in mantle cell lymphoma identifies a targetable vulnerability for ROR1-directed bispecific modalities.Leukemia202642823506PubTator, text miningPubMed
Multipronged enhancement of CART cell activity against ROR1 neoantigen by inhibition of H3K27 methyltransferase EZH2.Cell Rep Med202642790422PubTator, text miningPubMed
Targeting ROR1 with KAN571C disrupts resistance networks in mantle cell lymphoma.Blood Neoplasia202642733493PubTator, text miningPubMed
Preclinical development of ABL206, a novel bispecific antibody-drug conjugate targeting B7-H3 and ROR1.MAbs202642731893PubTator, text miningPubMed
Surface expression of ROR1 across lymphoma cell lines identifies models for preclinical evaluation of ROR1-targeting antibody-drug conjugates.Leuk Lymphoma202642704791PubTator, text miningPubMed
Retraction notice to "Theranostic silk sericin/SPION nanoparticles for targeted delivery of ROR1 siRNA: Synthesis, characterization, diagnosis and anticancer effect on triple-negative breast cancer" [Int. J. Biol. Macromol. 221 (2022) 604-612].
Int J Biol Macromol202642686485PubTator, text miningPubMed
Comprehensive analysis of senescence-associated secretory phenotype-related signature for predicting prognosis and immunotherapy response in cervical cancer.Comput Methods Biomech Biomed Engin202642643048PubTator, text miningPubMed
Therapeutic Effects of miR-29b-Enriched Nanovesicles on Mitochondrial Injury and Neuroinflammatory Processes in Alzheimer's Disease.Neurotox Res202642635855PubTator, text miningPubMed

1 to 10 of 2,258

See all 2,258 papers

Sources 12

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
  • GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
  • HGNCCC0
  • NCBI GenePublic domain (US government)
  • NIH's project files and grant-paper linksPublic domain
  • Open TargetsCC0 1.0
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
  • GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
  • HGNCCC0: https://www.genenames.org/about/license/
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this gene from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/genes/v1/4919

GET https://conductscience.org/api/genes/v1/4919/patents?page=2